Professor Vincenzo Libri

Carr, E.J., Dowgier, G., Greenwood, D., Herman, L.S., Hobbs, A., Ragno, M., … Libri, V., … Wu, M.Y. (2023). SARS-CoV-2 mucosal neutralising immunity after vaccination. The Lancet Infectious Diseases, https://doi.org/10.1016/S1473-3099(23)00705-3

Ramasamy, M.N., Kelly, E.J.,Seegobin, S., Dargan P.I., Payne, R., Libri, V., … Green, J.A. and the AZD2816 Study Group (2023). Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. The Lancet Microbe, https://doi.org/10.1016/S2666-5247(23)00177-5

Carr, E.J., Townsley, H., Wu, M.Y., Wilkinson, K.A., Hobson, P.S., Levi, D., … Libri. V., … Wall, E.C. (2023). Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults. BioRxiv Preprint, https://doi.org/10.1101/2023.05.24.541920

Townsley, H., Gahir, J., Russel, T.W., Carr, E.J., Dyke, M., Adams, L., … Libri, V., …Wall E.C. (2023). COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history. MedRxiv Preprint, https://doi.org/10.1101/2022.07.07.22277367

Carr, E.J., Wu, M.Y., Gahir, J., Harvey, R., Townsley, H., Bailey, C., … Libri. V., … Wall, E.C. on behalf of the Crick COVID Serology Consortium (2023). Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. The Lancet Infectious Diseases, https://doi.org/10.1016/S1473-3099(23)00289-X

Payne, T., Appleby, M., Buckley, E., van Gelder, L.M.A., Mullish, B.H., Sassani, M., … Libri, V., … Bandmann, O. (2023). A double-blind, randomized, placebo-controlled trial of Ursodeoxycholic Acid (UDCA) in Parkinson’s disease. Movement Disorders, https://doi.org/10.1002/mds.29450

Liu, X., Munro, A.P.S, Wright, A., Feng, S., Janani, L., Aley, P.K., … Libri, V., … Faust, S.N. and the COV-BOOST study group (2023). Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Journal of Infection, https://doi.org/10.1016/j.jinf.2023.04.012

Shaw, R.H., Greenland, M., Stuart, A.S.V., Aley, P.K., Andrews, N.J, Cameron, J., … Libri, V., … Snape, M.D. and the Com-COV2 Study Group (2023). Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, https://doi.org/10.1016/j.jinf.2023.03.027

Szubert, A.J., Pollock, K.M., Cheeseman, H.M., Alagaratnam, J., Bern, H., Bird, O., …Libri, V., …Shattock, R.J. on behalf of the COVAC 1 Study Team (2023). COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. The Lancet - eClinicalMedicine, https://doi.org/10.1016/j.eclinm.2022.101823

Marchevsky, N.G., Li, G., Aley P., Costa Clemens, S.A., Barrett, J.R., Belij-Rammerstorfer, S., …Voysey M and the Oxford COVID Vaccine Trial Group (…Libri, V., …) (2022). An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. The Lancet – eBioMedicine, https://doi.org/10.1016/j.ebiom.2022.104128

Mentzer, A.J., O’Connor, D., Bibi, S., Chelysheva, I., Clutterbuck, E.A., Demissie, T., …Oxford COVID Vaccine Trial Genetics Study Team Group (…Libri, V., …), Knight, J.C. (2022). Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, https://doi.org/10.1038/s41591-022-02078-6

Shaw, R.H., Liu, X., Stuart, A.S.V., Greenland, M., Aley, P.K., Andrews, N.J., …Libri, V., …Snape, M.D. and the Com-COV Study Group (2022). Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, https://doi.org/10.1016/S2213-2600(22)00163-1

Munro, A.P.S., Feng, S., Janani, L., Cornelius, V., Aley, P.K., Babbage, G., …Libri, V., …Faust SN, COV-BOOST study group (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. The Lancet Infectious Diseases, https://doi.org/10.1016/S1473-3099(22)00271-7

Levin, M., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., …Esser, M.T. for the PROVENT Study Group (…Libri, V., …) (2022). Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. New England Journal of Medicine, DOI: 10.1056/NEJMoa2116620

Liu, X., Munro, A.P.S., Feng, S., Janani, L., Aley, P.K., Babbage, G., …Libri, V., … Faust, S.N. and the COV-BOOST study group (2022). Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. Journal of Infection, https://doi.org/10.1016/j.jinf.2022.04.018

Mead, S., Khalili-Shirazi, A., Potter, C., Mok, T., Nihat, A., Hyare, H., …Libri, V, … Collinge, J. (2022). Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme. The Lancet Neurology, https://doi.org/10.1016/S1474-4422(22)00082-5

Wu, M., Wall, E.C, Carr, E.J., Harvey, R., Townsley, H., Mears, H.V., …Libri, V., … Bauer, D.L.V. (2022). Three-dose vaccination elicits neutralising antibodies against SARS-CoV-2 Omicron Variant. The Lancet, https://doi.org/10.1016/S0140-6736(22)00092-7

Pollock, K.M, Cheesemana, H.M., Szubertc, A.J., Libri, V., Boffito, M., Owen, D., … Shattock, R.J. on behalf of the COVAC1 study Group (2022). Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. The Lancet - eClinicalMedicine, https://authors.elsevier.com/sd/article/S2589537021005435

Fisher, B.A., Veenith, T., Slade, D., Gaskell, C., Rowland, M., Whitehouse, T., …Kearns, P. on behalf of the CATALYST investigators (…Libri, V., …) (2021). Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. The Lancet Respiratory Medicine, https://doi.org/10.1016/S2213-2600(21)00460-4

Dejnirattisai, W., Shaw, R.H., Supasa, P., Liu, C., Stuart, A.S.V., Pollard, A.J., … Screaton, G.R. and the Com-COV2 study group (…Libri, V., …) (2021). Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. The Lancet, https://doi.org/10.1016/S0140-6736(21)02844-0

Stuart, A.S.V., Shaw, R.H., Liu, X., Greenland, M., Aley, P.K., Andrews, N.J., …Libri, V., … Snape, M.D. and the Com-COV2 Study Group (2021). Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, https://doi.org/10.1016/S0140-6736(21)02718-5

Munro, A.P.S., Janani, L., Cornelius, V., Aley, P.K., Babbage, G., Baxter, D., …Libri, V., …

Faust, S.N. on behalf of the COV-BOOST Study Group (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, https://doi.org/10.1016/S0140-6736(21)02717-3

Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., …Libri, V, …Rogers, C.A. and the ComfluCOV Trial Group (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet, https://doi.org/10.1016/S0140-6736(21)02329-1

Hillson, K., Clemens, S.C., Madhi, S.A., Voysey, M., Pollard, A.J., Minassian, A.M. and the Oxford COVID Vaccine Trial Group (…Libri, V., …) (2021). Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. The Lancet, https://doi.org/10.1016/S0140-6736(21)02282-0

Feng, S., Phillips D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., …Voysey, M. and the Oxford COVID Vaccine Trial Group (…Libri, V., …) (2021). Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, https://doi.org/10.1038/s41591-021-01540-1

Swanson, P.A., Padilla, M., Hoyland, W., McGlinchey, K., Fields, P.A., Bibi, S., …Kelly, E.J. and the AstraZeneca/Oxford/VRC Study Group (…Libri, V., …) (2021). AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire. Science Translational Medicine, https://doi.org/10.1101/2021.06.17.21259027

Wall, E.C, Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., …Libri, V., … Bauer, D.L.V. (2021). AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. The Lancet, https://doi.org/10.1016/S0140-6736(21)01462-8

Liu, X., Shaw, R.H., Stuart, A.S.V, Greenland, M., Dinesh, T., …Libri, V., …Snape, M.D. and the Com-COV Study Group (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet, https://doi.org/10.1016/S0140-6736(21)01694-9

Flaxman, A., Marchevsky, N., Jenkin, S., Aboagye, J., Aley, P.K., …Lambe, T. and the Oxford COVID Vaccine Group (…Libri, V., …) (2021). Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet, https://doi.org/10.1016/S0140-6736(21)01699-8

Wall, E.C, Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., …Libri, V., … Bauer, D.L.V. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet https://doi.org/10.1016/S0140-6736(21)01290-3

Vijiaratnam, N., Girges, C., Auld, G., Chau, M., MacLagan, K., King, A., … Libri, V., Foltynie, T. (2021). Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease: protocol for a multi-centre, randomised, double blind, parallel group, placebo controlled, Phase 3 trial, The ‘Exenatide-PD3’ study. BMJ, http://dx.doi.org/10.1136/bmjopen-2020-047993

Emary, K.R.W., Golubchik, T., Aley, P.K., Ariani, C.V., Angus, B., Bibi, S., …Libri, V., …Pollard, A.J. and Oxford COVID Vaccine Trial Group (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet, https://doi.org/10.1016/S0140-6736(21)00628-0

Voysey, M., Costa Clemens S.A., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., …Libri, V., …Pollard, A.J. and Oxford COVID Vaccine Trial Group (2021). Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet, https://doi.org/10.1016/S0140-6736(21)00432-3

Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., …Libri, V., …Pollard, A.J. and Oxford COVID Vaccine Trial Group (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, doi:https://doi.org/10.1016/S0140-6736(20)32661-1

Mullin, S., Smith, L., Lee, K., D'Souza, G., Woodgate, P., Elflein, J, ...Libri, V., ..., Schapira, A. (2020). Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. A non-randomized, non-controlled trial. The Journal of the American Medical Association, doi:10.1001/jamaneurol.2019.4611

Tabrizi, S.J., Leavitt B.R., Landwehrmeyer, B., Wild, E., Saft, C., Barker, R.A., ...Lane, R.M. (Libri, V., in supplemental investigators list). (2019). Targeting Huntingtin Expression in Patients with Huntington’s Disease. New England Journal of Medicine, 380, 2307-2316. doi/10.1056/NEJMoa1900907

Reetz, K., Hilgers, R.D., Isfort, S., Dohmen, M., Didszun, C., Fedosov, K., … Libri, V., …Schulz, J.B. (2019). Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 1:33. doi.org/10.1186/s42466-019-0038-9

Mauricio, R., Benn, C., Davis, J., Dawson, G., Dawson, L.A., Evans, A., …Libri, V., ...Isaac, J. (2019). Tackling gaps in developing life-changing treatments for dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 5, 241-253. doi:10.1016/j.trci.2019.05.001

Kishnani, P., Lachmann, R., Mozaffar, T., Walters, C., Case, L., Appleby, M., ...Libri, V., Landy, H. (2019). Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Molecular Genetics and Metabolism, 126 (2), S85-S86. doi.org/10.1016/j.ymgme.2018.12.211

Quinn, K., Traboni, C., Penchala, S.D., Bouliotis, G., Doyle, N., Libri, V., ...Nicosia, A. (2017). A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol. Scientific Reports, 7. doi:10.1038/s41598-017-09230-0

Palleria, C., Cozza, G., Khengar, R., Libri, V., De Sarro, G. (2017). Safety profile of the newest antiepileptic drugs: a curated literature review. Current Pharmaceutical Design. doi:10.2174/1381612823666170809115429

Owen, D.R., Fan, J., Campioli, E., Venugopal, S., Midzak, A., Daly, E., …Libri, V., ... Papadopoulos, V. (2017). TSPO mutations in rats and a human polymorphism impair the rate of steroid synthesis. Biochemical Journal, 474 3985-3999. doi:10.1042/BCJ20170648

Libri, V., Gibbs, J.S.R., Pinato, D.J., Iddamalgoda, T., Khengar, R.H., Gin-Sing, W., ...Anand, P. (2014). Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. British Journal of Anaesthesia, 112 (2), 337-347. doi:10.1093/bja/aet308

Owen, D.R., Guo, Q., Kalk, N.J., Colasanti, A., Kalogiannopoulou, D., Dimber, R., …Libri, V., ... Rabiner, E.A. (2014). Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 34 (6), 989-994. doi:10.1038/jcbfm.2014.46

Libri, V., Yandim, C., Athanasopoulos, S., Loyse, N., Natisvili, T., Law, P.P., ...Tam, K.T. (2014). Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: An exploratory, open-label, dose-escalation study. The Lancet, 384 (9942), 504-513. doi:10.1016/S0140-6736(14)60382-2

Libri, V., Brown, A.P., Gambarota, G., Haddad, J., Shields, G.S., Dawes, H., ...Vlasuk, G.P. (2012). A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLOS ONE, 7 (12). doi:10.1371/journal.pone.0051395

Pinato, D.J., Stavraka, C., Tanner, M., Esson, A., Jacobson, E.W., Wilkins, M.R., Libri, V. (2012). Clinical, ethical and financial implications of incidental imaging findings: experience from a phase I trial in healthy elderly volunteers. PLOS ONE, 7 (11), doi:10.1371/journal.pone.0049814

Lythe, K.E., Williams, S.C.R., Anderson, C., Libri, V., Mehta, M.A. (2012). Frontal and parietal activity after sleep deprivation is dependent on task difficulty and can be predicted by the fMRI response after normal sleep. Behavioural Brain Research, 233 (1), 62-70. doi:10.1016/j.bbr.2012.04.050

Devanand, D.P., Mikhno, A., Pelton, G.H., Cuasay, K., Pradhaban, G., Dileep Kumar, J.S., ...Libri, V., …Parsey, R.V. (2010). Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. Journal of Geriatric Psychiatry and Neurology, 23 (3), 185-198. doi:10.1177/0891988710363715

Thompson, P.W., Ye, L., Morgenstern, J.L., Sue, L., Beach, T.G., Judd, D.J., …Libri, V., ...Lockhart, A. (2009). Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. Journal of Neurochemistry, 109 (2), 623-630. doi:10.1111/j.1471-4159.2009.05996.x

Jones, N., Messenger, M.J., O'Neill, M.J., Oldershaw, A., Gilmour, G., Simmons, R.M.A., …Libri, V., ...Williams, S.C.R. (2008). AMPA receptor potentiation can prevent ethanol-induced intoxication. Neuropsychopharmacology, 33 (7), 1713-1723. doi:10.1038/sj.npp.1301562

Ye, L., Velasco, A., Fraser, G., Beach, T.G., Sue, L., Osredkar, T., …Libri, V., ...Lockhart, A. (2008). In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. Journal of Neurochemistry, 105 (4), 1428-1437. doi:10.1111/j.1471-4159.2008.05245.x

Mikhno, A., Devanand, D., Pelton, G., Cuasay, K., Gunn, R., Upton, N., …Libri, V., ...Parsey, R.V. (2008). Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. Journal of Nuclear Medicine, 49 (8), 1262-1269. doi:10.2967/jnumed.107.049932

Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., …Libri, V., ...Beach, T.G. (2007). PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain, 130 2607-2615. doi:10.1093/brain/awm191

Jones, N., O'Neill, M.J., Tricklebank, M., Libri, V., Williams, S.C.R. (2005). Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology, 180 (4), 743-751. doi:10.1007/s00213-005-2254-y

Giffin, N.J., Kowacs, F., Libri, V., Williams, P., Goadsby, P.J., Kaube, H. (2003). Effect of the adenosine A(1) receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalagia, 23 (4), 287-292. DOI:10.1046/j.1468-2982.2003.00511.x

McCarthy, L.C., Hosford, D.A., Riley, J.H., Bird, M.I., White, N.J., Hewett, D.R., …Libri, V., ...Lea, R.A. (2001). Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics, 78 (3), 135-149. doi:10.1006/geno.2001.6647

Postlethwaite, M., Constanti, A., Libri, V. (2000). Investigation of the role of intracellular Ca(2+) stores in generation of the muscarinic agonist-induced slow afterdepolarization (sADP) in guinea-pig olfactory cortical neurones in vitro. British Journal of Pharmacology, 129 (7), 1447-1457. doi:10.1038/sj.bjp.0703236

Chimirri, A., De Sarro, G., De Sarro, A., Gitto, R., Quartarone, S., Zappalà, M., ...Libri, V. (1998). 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists. Journal of Medicinal Chemistry, 41 (18), 3409-3416. doi:10.1021/jm9800393

Libri, V., Constanti, A., Postlethwaite, M., Bowery, N.G. (1998). Blockade of GABA(B) receptors facilitates muscarinic agonist-induced epileptiform activity in immature rat piriform cortex in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 358 (2), 168-174. doi:10.1007/PL00005239

Postlethwaite, M., Constanti, A., Libri, V. (1998). Muscarinic agonist-induced burst firing in immature rat olfactory cortex neurons In vitro. Journal of Neurophysiology, 79 (4), 2003-2012

Chimirri, A., De Sarro, G., De Sarro, A., Gitto, R., Grasso, S., Quartarone, S., …Libri, V., ...Chapman, A.G. (1997). 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. Journal of Medicinal Chemistry, 40 (8), 1258-1269. doi:10.1021/jm960506l

Libri, V., Santarelli, R., Nisticò, S., Azzena, G.B. (1997). Inhibition of nitric oxide synthase prevents magnesium-free-induced epileptiform activity in guinea-pig piriform cortex neurones in vitro. Naunyn-Schmiedebergs Archives of Pharmacology, 355 (4), 452-456. doi:10.1007/PL00004968

Libri, V., Constanti, A., Zibetti, M., Postlethwaite, M. (1997). Metabotropic glutamate receptor subtypes mediating slow inward tail current (IADP) induction and inhibition of synaptic transmission in olfactory cortical neurones. British Journal of Pharmacology, 120 (6), 1083-1095. doi:10.1038/sj.bjp.0701021

Libri, V., Constanti, A., Zibetti, M., Nisticó, S. (1996). Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. Journal of Pharmacology and Experimental Therapeutics, 277 (3), 1759-1769

Libri, V., Constanti, A., Bowery, N.G. (1996). Role of GABA(B) receptor down-regulation in the generation of epileptiform activity in disinhibited rat olfactory cortical neurones. Pharmacology Communications, 8 (2-3), 185-190

Malcangio, M., Libri, V., Teoh, H., Constanti, A., Bowery, N.G. (1995). Chronic (-)baclofen or CGP 36742 alters GABAB receptor sensitivity in rat brain and spinal cord. Neuroreport, 6 (2), 399-403. doi.org/10.1097/00001756-199501000-00042

Libri, V., Constanti, A., Calaminici, M., Nisticó, G. (1994). A comparison of the muscarinic response and morphological properties of identified cells in the guinea-pig olfactory cortex in vitro. Neuroscience, 59 (2), 331-347. doi:10.1016/0306-4522(94)90600-9

Libri, V., Scorsa, A.M., Dawe, G., Nisticó, G. (1994). Long-term potentiation of synaptic transmission in rodents: Effects of pramiracetam sulphate. Pharmacology Communications, 4 (2), 125-135

Harris, N.C., Libri, V., Constanti, A. (1994). Selective blockade of the hyperpolarization-activated cationic current (Ih) in guinea pig substantia nigra pars compacta neurones by a novel bradycardic agent, Zeneca ZM 227189. Neuroscience Letters, 176 (2), 221-225. doi:10.1016/0304-3940(94)90087-6

Libri, V., Giglio, A., Nisticó, G. (1993). Evidence that nitric oxide modulates learning processes and memory in mice. Pharmacology Communications, 3 (1), 81-88

Constanti, A., Bagetta, G., Libri, V. (1993). Persistent muscarinic excitation in guinea-pig olfactory cortex neurons: involvement of a slow post-stimulus afterdepolarizing current. Neuroscience, 56 (4), 887-904. doi:10.1016/0306-4522(93)90135-3

Das, B., Libri, V., Constanti, A. (1992). Carbachol-evoked suppression of excitatory neurotransmission in guinea-pig olfactory cortex slices is unlikely to involve an M4-muscarinic receptor subtype. Functional Neurology, 7 (2), 135-140

Libri, V., Das, B., Constanti, A. (1992). Ganglionicnicotinic receptor agonists exhibit anti-muscarinic effects in guinea-pig olfactory cortical brain slices. European Journal of Pharmacology, 212 (2-3), 253-258. doi:10.1016/0014-2999(92)90338-5

Libri, V., Constanti, A., Bagetta, G., Nisticò, G. (1992). Metabotropic (glutamate) receptor agonists induce a post-stimulus afterdepolarization in guinea-pig olfactory cortex neurones in vitro. Pharmacological Research, 26 (1), 215. doi:10.1016/1043-6618(92)91139-8

Constanti, A., Libri, V. (1992). Trans-ACPD induces a slow poststimulus inward tail current (IADP) in guinea-pig olfactory cortex neurones in-vitro. European Journal of Pharmacology, 214 (1), 105-106. doi:10.1016/0014-2999(92)90105-D

Priolo, E., Libri, V., Lopilato, R., David, E., Nappi, G., Nisticò, G. (1991). Panic-like attack induced by microinfusion into the locus coeruleus of antagonists and inverse agonists at GABAA-receptors in rodents. Functional Neurology, 6 (4), 393-403

Libri, V., Del Gobbo, V., Villani, N., Caliò, R., Nisticò, G. (1990). Influence of pineal gland lesion on interleukin-2 production and natural killer activity in C57BL/6 mice. Pharmacological Research, 22 52-. doi:10.1016/S1043-6618(09)80024-8

De Sarro, G.B., Ascioti, C., Audino, M.G., Libri, V., De Sarro, A., Nisticò, G. (1989). Behavioural and electrocortical effects after injection of two ornithine decarboxylase inhibitors into several areas of the brain in the rat. Neuropharmacology, 28 (11), 1245-1251. doi:10.1016/0028-3908(89)90218-9

Libri, V., Ammassari-Teule, M., Castellano, C. (1989). Blocking of morphine-induced locomotor hyperactivity by amygdaloid lesions in C57BL/6 mice. Brain Research, 479 (1), 1-5. doi:10.1016/0006-8993(89)91328-0

De Sarro, G.B., Bagetta, G., Ascioti, C., Libri, V., Nisticò, G. (1989). Effects of pertussis toxin on the behavioural and ECoG spectrum changes induced by clonidine and yohimbine after their microinfusion into the locus coeruleus. British Journal of Pharmacology, 96 (1), 59-64. http://dx.doi.org/10.1111/j.1476-5381.1989.tb11784.x

Del Gobbo, V., Libri, V., Villani, N., Caliò, R., Nisticò, G. (1989). Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. International Journal of Immunopharmacology, 11 (5), 567-573. doi:10.1016/0192-0561(89)90187-2

De Sarro, A., De Sarro, G.B., Ascioti, C., Libri, V., Nisticò, G. (1988). Comparative epileptogenic activity of various ß-lactam derivatives in rats. Pharmacological Research Communications, 20 (2), 129. doi:10.1016/S0031-6989(88)80259-5

Libri, V., Ammassari-Teule, M., Castellano, C. (1988). Effects of amygdaloid-lesions on morphine-induced hyperactivity in C57BL/6 mice. Pharmacological Research Communications, 20 (3), 251-252. doi:10.1016/S0031-6989(88)80061-4

Castellano, C., Ammassari-Teule, M., Libri, V., Pavone, F. (1988). Effects of kappa-opioid receptor agonists on locomotor activity and memory processes in mice. Polish Journal of Pharmacology and Pharmacy, 40 (5), 507-513

Sansone, M., Libri, V., Pavone, F., Ammassari-Teule, M. (1988). Effects of oxiracetam-scopolamine combinations on shuttle-box avoidance acquisition in mice. Archives Internationales De Pharmacodynamie Et De Therapie, 291 208-216

De Sarro, G.B., Bagetta, G., Ascioti, C., Libri, V., Nisticò, G. (1988). Microinfusion of clonidine and yohimbine into locus coeruleus alters EEG power spectrum: effects of aging and reversal by phosphatidylserine. British Journal of Pharmacology, 95 (4), 1278-1286. doi.org/10.1111/j.1476-5381.1988.tb11765.x

Castellano, C., Libri, V., Ammassari-Teule, M. (1988). The amygdala mediates the impairing effect of the selective kappa-opioid receptor agonist U-50,488 on memory in CD1 mice. Behavioural Brain Research, 30 (3), 259-263. doi:10.1016/0166-4328(88)90168-4

Sansone, M., Castellano, C., Libri, V. (1988). Tripelennamine enhances buprenorphine-, but not pentazocine-induced hyperactivity in mice. Psychopharmacology, 95 (2), 176-179. doi.org/10.1007/bf00174505 

De Sarro, G.B., Libri, V., Ascioti, C., Testa, R., Nisticó, G. (1987). Anticonvulsant effect of denzimol in DBA/2 mice. Neuropharmacology, 26 (9), 1425-1429. doi:10.1016/0028-3908(87)90109-2

De Sarro, G.B., Ascioti, C., Froio, F., Libri, V., Nisticò, G. (1987). Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. British Journal of Pharmacology. http://dx.doi.org/10.1111/j.1476-5381.1987.tb11220.x

De Sarro, G.B., Ascioti, C., Fersini, G., Libri, V., Marmo, E., Nisticò, G. (1986). Behavioral and electrocortical effects of tolonidine in rats. Research Communications in Chemical Pathology and Pharmacology, 54 (3), 299-312

Selected conference papers/abstracts

Ramasamy, M.N., Kelly, E.J., Seegobin, S., Dargan, P.I., Payne, R., Libri, V., …Green, J. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) and AZD2816 as third-dose boosters in adults previously vaccinated with AZD1222 or an mRNA vaccine. 32nd European Congress of Clinical Microbiology & Infectious Diseases, Lisbon, Portugal 23-26 April 2022.

Kishnani, P., Lachmann, R., Mozaffar, T., Walters, C., Case, L., Appleby, M., ...Libri, V., Landy, H. (2019). Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Molecular Genetics and Metabolism, 126 (2), S85-S86, meeting abstract: 195

Quinn, K., Bouliotis, G., Doyle, N., Winston, A., Ashby, D., Weber, J., ...Libri, V., Penchala, S.D. (2016). A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol. HIV Medicine, 17 (1) 18-18, Special Issue: SI meeting abstract: P13

Nageshwaran, S., Athanasopoulos, S., Georgiadou, C., Yandim, C., Natisvili, T., Law, P.P., ...Libri, V., Giunti, P. (2015). Nicotinamide given once daily is more effective than twice daily at increasing frataxin expression in Friedreich's ataxia. Movement Disorders, 30 (1), S363-S363, meeting abstract: 934

Devanand, D.P., Mikhno, A., Pelton, G.H., Cuasay, K., Kumar, J.S.D., Upton, N., … Libri, V., Parsey, R.V. (2009). Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, Mild Cognitive Impairment and healthy controls. Alzheimer's & Dementia (Suppl), 5 (4), P16-P17, meeting abstract

Devanand, D.P., Mikhno, A., Pelton, G.H., Cuasay, K., Kumar, J.S.D., Tabert, M.H., …Libri, V., Parsey, R.V. (2008). PET amyloid imaging with Pittsburgh Compound B in Alzheimer's disease, Mild Cognitive Impairment, and Healthy Controls. Alzheimer's & Dementia (Suppl), 4 (4), T282, meeting abstract

Mikhno, A, Devanand, D.P., Pelton, G.H., Cuasay, K., Gunn, R.N., Upton, N., …Libri, V., Parsey, R.V. (2008). Voxel-based Analysis Of C11 Pittsburgh Compound B For Diagnosing Alzheimer's Disease. Alzheimer's & Dementia (Suppl), 4 (4), T294, 2008, meeting abstract

Pan, M., Chuah, Y.M.L., Chong, D., Tan, J.C., Rekshan, W., Chen, A., …Libri, V., Chee, M.W.L. (2008). The neurocognitive benefits of donepezil on episodic memory in young, healthy individuals following 24 h of sleep deprivation. Alzheimer's & Dementia (Suppl), 4 (4), T506-T507, 2008, meeting abstract

Pan, M., Chuah, Y.M.L., Chen, A., Chong, D., Rekshan, W., …Libri, V., Chee, M.W.L. (2008). The neurocognitive effects of donepezil on visual short-term memory capacity following 24 h of sleep deprivation. Alzheimer's & Dementia (Suppl), 4 (4), T507-T508, 2008, meeting abstract

Lai, R., Gregory, G., Hall, D.L., Kenny, G., Caceres, A., Libri, V., …Mehta, M.A. (2008). A novel potent Histamine H3 receptor antagonist produces discrete changes in brain activity during learning and episodic memory: implications for cognitive enhancement. Alzheimer's & Dementia (Suppl), 4 (4), T503-T504, 2008, meeting abstract

Postlethwaite, M., Constanti, A., Libri, V. (1999). Caffeine blocks the post-stimulus afterdepolarising tail current (I-ADP) induced by muscarinic receptor activation in olfactory cortical neurones in vitro. British Journal of Pharmacology (Proc Suppl), 129, 292P, meeting abstract

Libri, V., Constanti, A., Zibetti, M., Postlethwaite, M. (1997). Pre- and post-synaptic metabotropic glutamate receptor pharmacology in guinea-pig olfactory cortical neurones in vitro. British Journal of Pharmacology (Proc Suppl), 120 P354, meeting abstract

Postlethwaite, M., Constanti, A., Libri, V. (1997). Epileptiform potentials induced by muscarinic but not metabotropic-glutamate receptor activation in immature rat olfactory cortex, in vitro. British Journal of Pharmacology (Proc Suppl), 122 P84, meeting abstract

Libri, V., Constanti, A., Nisticò, S., Bowery, N.G. (1996). Involvement of GABA-B receptor down-regulation in cortical epileptogenesis. Fundamental & Clinical Pharmacology, 10, 199, meeting abstract

Libri, V., Constanti, A., Bowery, N.G. (1996). Role of GABA(B) receptor down-regulation in the generation of epileptiform activity in disinhibited rat olfactory cortical neurones. Pharmacology: Reviews and Communications, 8 (2-3), 185-190, special issues: 3rd international GABA(B) symposium, proceedings paper

Libri, V., Constanti, A., Bowery, N.G. (1995). GABA(B) receptor down-regulation facilitates muscarinic or metabotropic agonist-dependent burst firing in rat olfactory cortical-beurons, in-vitro. Journal of Pharmacology (Proc Suppl), 116, P 332, meeting abstract

Libri, V., Constanti, A. (1995). Antagonism by felbamate of muscarinic and metabotropic receptor mediated responses in guinea-pig olfactory cortex neurones in vitro. British Journal of Pharmacology (Proc Suppl), 114, P 333, meeting abstract

Bowery, N.G., Constanti, A., Fowler, L., Libri, V., Lemos, T., Malcangio, M., ...Whitton, P. (1995). GABA-B receptor plasticity. Journal of Neurochemistry, 65 S3. meeting abstract

Schindler, U., Libri, V., Nisticò, G. (1993). Inhibitors of nitric oxide synthase impair passive and active avoidance learning in rodents. Nitric oxide: brain and immune system, 181-189, Portland Press, proceedings paper

Carletti, R., Libri, V., Bowery, N.G. (1993). The GABA(B) antagonist CGP 36742 enhances spacia-learning performance and antagonizes baclofen-induced amnesia in mice. British Journal of Pharmacology (Proc Suppl), 109 P74, meeting abstract

Das, B., Libri, V., Constanti, A. (1992). Muscarinic suppression of excitatory neurotransmission in guinea-pig olfactory cortex slices is unlikely to involve an M4-muscarinic receptor. British Journal of Pharmacology (Proc Suppl), 106, 141P, meeting abstract

Libri, V., Das, B., Constanti, A. (1991). Anti-muscarinic effects of some ganglionic nicotinic receptor agonists in guinea-pig olfactory cortex slices. British Journal of Pharmacology (Proc Suppl), 104, 459P, meeting abstract

Ascioti, C., De Sarro, G.B., Froio, F., Libri, V., Nisticò G. (1985). Locus Coeruleus: site of sedation and sleep induced by clonidine. British Journal of Pharmacology (Proc Suppl), 86, 676P, meeting abstract

Ascioti, C., De Sarro, G.B., Froio, F., Libri, V., Nisticò G. (1985). Locus Coeruleus: site of sedation and sleep induced by clonidine. British Journal of Pharmacology (Proc Suppl), 86, 676P

Book Chapters

Libri, V. (2010). Experimental medicine endpoints in early-phase clinical trials for CNS indications. In “Forty Years of Advances in Pharmacology”. Nistico, Rotiroti, De Sarro, Mollace Eds, pp. 152-165

Libri, V., Nisticò, G. (1994). Modelli di Farmacologia Sperimentale: effetti dei nuovi acetam-derivati. In: Modelli di ricerca neurologica applicata, ASK Eds, pp. 7-19

Schindler, U., Libri, V., Nisticò, G. (1993) Inhibitors of nitric oxide synthase impair passive and active avoidance learning in rodents. In: Nitric oxide: brain and immune system. Portland Press Proceedings, S. Moncada, G. Nisticò and E.A. Higgs Eds, pp. 181-189

Del Gobbo, V., Libri, V., Villani, N., Caliò, R., Nisticò, G. (1989). Role of the pineal gland in the control of interleukin-2 production and natural killer activity in mice. In: Interactions among CNS, Neuroendocrine and Immune system. Pythagora Press, Rome-Milan, pp. 81-91.

De Sarro, G.B., Ascioti, C., Bagetta, G., Libri, V., Nisticò, G. (1986). Behavioural and electrocortical changes of the polyamines after their microinfusion in several areas of the rat brain. In: Neurotransmitters, seizures and epilepsy III. Raven Press, New York, pp. 423-438